Breaking News

Definiens, Clarient Expand Imaging Analysis Pact

By Kristin Brooks | February 3, 2014

To offer validated applications for clinical pathology

Definiens, a provider of image analysis for digital pathology and diagnostics, has entered an agreement with Clarient Diagnostic Services, expanding the use of Definiens’ automated image analysis software and solutions in Clarient's validated clinical applications for immunohistochemistry testing in breast cancer. Definiens' Cognition Network Technology automatically classifies and quantitates key tissue features as part of Clarient's Scope IA Platform offering.
"At Clarient, we combine world class pathology with innovation and our goal is to make a difference to physicians and their patients," said Kenneth Bloom, MD, chief medical officer, Clarient Diagnostic Services. "Our work with Definiens will enable us to offer high quality, robust readouts with fast turnaround time. This means physicians will have better patient insights for diagnosis."
"We are really pleased to work with Clarient on creating these validated applications for their routine clinical work. Running thousands of patient slides through our algorithms and seeing the computer-aided diagnosis in action is really gratifying," said Thomas Heydler, chief executive officer of Definiens.  
blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Setting a Precedent for Biosimilars in the U.S.

    Setting a Precedent for Biosimilars in the U.S.

    Kristin Brooks, Contract Pharma||May 19, 2015
    Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain

  • API Sourcing Trends

    API Sourcing Trends

    Kristin Brooks, Contract Pharma||March 19, 2015
    Ed Price of PCI Synthesis addresses trends, regulatory and supply chain hurdles, and quality concerns

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Biopharma CMO Market Trends

    Biopharma CMO Market Trends

    Tim Wright, Editor||June 2, 2016
    Continued strong growth in biopharma industry is being driven by biosimilars

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.